Thymosin α1

Prothymosin, alpha

NMR structure of thymosin alpha-1. PDB 2l9i [1]
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols PTMA ; TMSA
External IDs OMIM: 188390 MGI: 97803 HomoloGene: 136511 GeneCards: PTMA Gene
Orthologs
Species Human Mouse
Entrez 5757 100504173
Ensembl ENSG00000187514 ENSMUSG00000026238
UniProt P06454 P26350
RefSeq (mRNA) NM_001099285 n/a
RefSeq (protein) NP_001092755 n/a
Location (UCSC) Chr 2:
231.71 – 231.71 Mb
Chr 1:
86.53 – 86.53 Mb
PubMed search

Thymosin α1 is a peptide fragment derived from prothymosin alpha, a protein that in humans is encoded by the PTMA gene.[2]

Function

Thymosin α1 is believed to be a major component of Thymosin Fraction 5 responsible for the activity of that preparation in restoring immune function in animals lacking thymus glands. It was the first of the peptides from Thymosin Fraction 5 to be completely sequenced and synthesized. Unlike β thymosins, to which it is genetically and chemically unrelated, thymosin α1 is produced as a 28-amino acid fragment, from a longer, 113-amino acid precursor, prothymosin α.[3] It has been found to enhance cell-mediated immunity in humans as well as experimental animals.[4]

Therapeutic application

Thymosin α1 is now approved in 35 under developed or developing countries for the treatment of Hepatitis B and C, and it is also used to boost the immune response in the treatment of other diseases.[5][6]

See also

References

  1. Elizondo-Riojas, M. A.; Chamow, S. M.; Tuthill, C. W.; Gorenstein, D. G.; Volk, D. E. (2011). "NMR structure of human thymosin alpha-1". Biochemical and Biophysical Research Communications 416 (3–4): 356–361. doi:10.1016/j.bbrc.2011.11.041. PMC 3419376. PMID 22115779.
  2. Manrow RE, Leone A, Krug MS, Eschenfeldt WH, Berger SL (Jul 1992). "The human prothymosin alpha gene family contains several processed pseudogenes lacking deleterious lesions". Genomics 13 (2): 319–31. doi:10.1016/0888-7543(92)90248-Q. PMID 1612591.
  3. Garaci E (September 2007). "Thymosin alpha1: a historical overview". Ann. N. Y. Acad. Sci. 1112: 14–20. doi:10.1196/annals.1415.039. PMID 17567941.
  4. Wara DW, Goldstein AL, Doyle NE, Ammann AJ (January 1975). "Thymosin activity in patients with cellular immunodeficiency". N. Engl. J. Med. 292 (2): 70–4. doi:10.1056/NEJM197501092920204. PMID 1078552.
  5. Garaci E, Favalli C, Pica F, et al. (September 2007). "Thymosin alpha 1: from bench to bedside". Ann. N. Y. Acad. Sci. 1112: 225–34. doi:10.1196/annals.1415.044. PMID 17600290.
  6. Goldstein AL, Goldstein AL (May 2009). "From lab to bedside: emerging clinical applications of thymosin alpha 1". Expert Opin Biol Ther 9 (5): 593–608. doi:10.1517/14712590902911412. PMID 19392576.

Further reading

This article is issued from Wikipedia - version of the Wednesday, September 02, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.